A Case of Drug Eruption with Periorbital Edema and Exfoliative Dermatitis Induced by Imatinib Mesylate (STI571, Gleevec(TM)).
- Author:
Young Hyun JOO
1
;
Seong Uk MIN
;
Dong Hun LEE
;
Dae Hun SUH
Author Information
1. Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. daehun@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Drug eruption;
Exfoliative dermatitis;
Imatinib mesylate;
Periorbital edema;
STI571
- MeSH:
Dermatitis, Exfoliative*;
Drug Eruptions*;
Edema*;
Gastrointestinal Stromal Tumors;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates*;
Phosphotransferases;
Receptors, Platelet-Derived Growth Factor;
Tyrosine;
Imatinib Mesylate
- From:Korean Journal of Dermatology
2007;45(2):194-196
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
STI571 (imatinib mesylate, Gleevec(TM)), a selective inhibitor of the bcr-abl, c-kit, platelet-derived growth factor receptor tyrosine kinases, is a new anticancer drug used for chronic myelogenous leukemia and gastrointestinal stromal tumors. Cutaneous adverse reactions of periorbital edema and exfoliative dermatitis related to STI571 are rare and there have been no previous reports in the Korean literature. We herein report a case of periorbital edema and exfoliative dermatitis due to STI571 and discuss the possible mechanism of periorbital edema related to STI571.
